Market Snapshot
| Study Period: | 2018 - 2026 |
| Base Year: | 2021 |
| CAGR: | 12.5 % |
|
Need a report that reflects how COVID-19 has impacted this market and its growth?
Market Overview
The North America Proteomics Market is expected to register a CAGR of 12.5% during the forecast period. The major factors driving the growth of the market include rising demand for personalized medicine, increasing R&D expenditure and government funding for proteomics and technological advancements in proteomics.
Personalized medicine has become a core area of research in the healthcare industry and entered mainstream clinical practice and is changing the way many diseases are identified and treated. Furthermore, increasing investments in the development of structure-based drug designs, rising demand for high-quality research tools for data reproducibility, and increasing focus on developing personalized therapeutics.
According to the Pharmaceutical Research and Manufacturers of America (PhRMA), in 2018, the United States pharmaceutical industry invested around USD 79.6 billion on research and development which was increased from USD 71.4 billion in 2017. In addition, presence of key market players in North America region is another key factor contributing to the large share of this market segment.
Scope of the report
As per scope of the report, proteomics is the study of protein structure and function. At the cellular level, proteomics deal with the topics, such as which proteins are expressed, when and where they are expressed, what their structures in both active and inactive states are, what roles they play in the life of the cell, and how they interact with other proteins and molecules. The North America Proteomics Market is segmented by Instrumentation Technology, Services and Software, Reagents, Application (Clinical Diagnostics, Drug Discovery, Other Applications), and Geography.
Key Market Trends
Drug Discovery is Expected to Witness Healthy CAGR in Future
The identification of potential new drugs for the treatment of disease has been considered one of the most promising developments in the study of human genes and proteins. This depends on genome and proteome information for the identification of proteins, associated with a disease, which can then be used as targets for new drugs by computer software.
Furthermore, preclinical stages in the process of drug discovery need a multitude of genetic and biochemical assays in order to characterize the effects of drug candidates on cellular systems as well as model organisms.
Growing investment on research and development is also expected to drive market growth. For instance, according to the Organisation for Economic Co-operation and Development (OECD), in 2017, biotechnology companies in United States spent approximately USD 44,793 million annually in research and development.
This indicates the increasing investment in healthcare research and development which is expected to boost the market over the forecast period. Thus, owing to above mentioned factors it is expected to show significant growth over the forecast period.
To understand key trends, Download Sample Report
Competitive Landscape
The North America Proteomics Market is highly competitive. Companies like Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Bruker Corporation, Danaher Corporation, GE Healthcare, Merck KGaA, Promega Corporation, Thermo Fisher Scientific, Inc., and Waters Corporation, among others, hold the substantial share in the proteomics market.
Table of Contents
-
1. INTRODUCTION
-
1.1 Study Assumptions
-
1.2 Scope of the Study
-
-
2. RESEARCH METHODOLOGY
-
3. EXECUTIVE SUMMARY
-
4. MARKET DYNAMICS
-
4.1 Market Overview
-
4.2 Market Drivers
-
4.2.1 Rising Demand for Personalized Medicine
-
4.2.2 Increasing R&D Expenditure and Government Funding for Proteomics
-
4.2.3 Technological Advancements
-
-
4.3 Market Restraints
-
4.3.1 High Cost of Instruments
-
-
4.4 Porter's Five Force Analysis
-
4.4.1 Threat of New Entrants
-
4.4.2 Bargaining Power of Buyers/Consumers
-
4.4.3 Bargaining Power of Suppliers
-
4.4.4 Threat of Substitute Products
-
4.4.5 Intensity of Competitive Rivalry
-
-
-
5. MARKET SEGMENTATION
-
5.1 By Type
-
5.1.1 By Instrumentation Technology
-
5.1.1.1 Spectroscopy
-
5.1.1.2 Chromatography
-
5.1.1.3 Electrophoresis
-
5.1.1.4 Protein Microarrays
-
5.1.1.5 X-Ray Crystallography
-
5.1.1.6 Other Instrumentation Technologies
-
-
5.1.2 By Services and Software
-
5.1.2.1 Core Proteomics Services
-
5.1.2.2 Bioinformatics Software and Services
-
-
5.1.3 By Reagents
-
-
5.2 By Application
-
5.2.1 Clinical Diagnostics
-
5.2.2 Drug Discovery
-
5.2.3 Other Applications
-
-
5.3 Geography
-
5.3.1 North America
-
5.3.1.1 United States
-
5.3.1.2 Canada
-
5.3.1.3 Mexico
-
-
-
-
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
-
6.1.1 Agilent Technologies, Inc.
-
6.1.2 Bio-Rad Laboratories, Inc.
-
6.1.3 Thermo Fisher Scientific, Inc.
-
6.1.4 Danaher Corporation (Cytiva)
-
6.1.5 Merck KGaA (Sigma-Aldrich)
-
6.1.6 Bruker Corporation
-
6.1.7 Promega Corporation
-
6.1.8 Waters Corporation
-
6.1.9 Bruker Corporation
-
*List Not Exhaustive -
-
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The North America Proteomics Market market is studied from 2018 - 2026.
What is the growth rate of North America Proteomics Market?
The North America Proteomics Market is growing at a CAGR of 12.5% over the next 5 years.
Who are the key players in North America Proteomics Market?
Agilent Technologies, Inc, Bio-Rad Laboratories, Inc, Thermo Fisher Scientific, Inc., Danaher Corporation (Cytiva), Merck KGaA (Sigma-Aldrich) are the major companies operating in North America Proteomics Market.
